Vanguard Group Inc. Grows Stock Position in Cerus Co. (NASDAQ:CERS) (2024)

Vanguard Group Inc. increased its holdings in Cerus Co. (NASDAQ:CERS – Free Report) by 1.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,983,963 shares of the biotechnology company’s stock after buying an additional 113,292 shares during the quarter. Vanguard Group Inc. owned 5.40% of Cerus worth $18,870,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in CERS. Neuberger Berman Group LLC bought a new stake in shares of Cerus during the 4th quarter valued at $26,000. Russell Investments Group Ltd. grew its holdings in Cerus by 451.1% during the first quarter. Russell Investments Group Ltd. now owns 14,879 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 12,179 shares during the period. RPO LLC purchased a new stake in Cerus in the fourth quarter worth about $79,000. Virtu Financial LLC bought a new position in shares of Cerus in the fourth quarter worth about $180,000. Finally, Aristides Capital LLC purchased a new position in shares of Cerus during the 4th quarter valued at about $231,000. 78.37% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Cantor Fitzgerald raised their price objective on shares of Cerus from $3.00 to $4.00 and gave the company an “overweight” rating in a research report on Friday, May 3rd.

Get Our Latest Research Report on CERS

Cerus Stock Down 1.8 %

CERS opened at $2.14 on Monday. Cerus Co. has a 52 week low of $1.21 and a 52 week high of $2.59. The company has a quick ratio of 1.72, a current ratio of 2.41 and a debt-to-equity ratio of 1.29. The firm has a 50-day simple moving average of $1.98 and a two-hundred day simple moving average of $1.96. The company has a market capitalization of $395.66 million, a PE ratio of -12.59 and a beta of 1.20.

Cerus (NASDAQ:CERS – Get Free Report) last posted its earnings results on Thursday, August 1st. The biotechnology company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. Cerus had a negative return on equity of 44.14% and a negative net margin of 14.15%. The firm had revenue of $45.08 million during the quarter, compared to the consensus estimate of $42.50 million. During the same period in the prior year, the company earned ($0.07) EPS. Analysts forecast that Cerus Co. will post -0.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Cerus news, insider Richard J. Benjamin sold 21,605 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $2.50, for a total transaction of $54,012.50. Following the sale, the insider now directly owns 438,007 shares in the company, valued at $1,095,017.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 3.40% of the stock is currently owned by company insiders.

About Cerus

(Free Report)

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Featured Stories

• Five stocks we like better than Cerus
• What is the Euro STOXX 50 Index?
• Why Wall Street Analysts Raised Price Targets for Suncor Stock
• What is a Secondary Public Offering? What Investors Need to Know
• Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
• Pros And Cons Of Monthly Dividend Stocks
• MarketBeat Week in Review – 8/5 – 8/9

Want to see what other hedge funds are holding CERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerus Co. (NASDAQ:CERS – Free Report).

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.